Improved humoral immunogenicity with mRNA‐1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses
Amy Chang(Johns Hopkins University), William A. Werbel(Johns Hopkins University), Alexa Jefferis(Johns Hopkins University), Teresa Po‐Yu Chiang(Johns Hopkins University), Allan B. Massie(Johns Hopkins University), Dorry L. Segev(New York University), Jonathan Mitchell(Johns Hopkins University), Robin K. Avery(Johns Hopkins University), Daniel Warren(Johns Hopkins University), Jacqueline Garonzik‐Wang(University of Wisconsin–Madison), Aaron A.R. Tobian(Johns Hopkins University), Macey L. Levan(New York University), Jennifer L. Alejo(Johns Hopkins University), Jake D. Kim(Johns Hopkins University)
Cited by 2
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
Clinical Practice Guidelines From the AABB
|JAMA|2016|1.1k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863